Biren Amin
Stock Analyst at Piper Sandler
(3.39)
# 904
Out of 5,182 analysts
73
Total ratings
41.54%
Success rate
6.41%
Average return
Main Sectors:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $875 | $761.85 | +14.85% | 3 | Mar 31, 2026 | |
| CNTX Context Therapeutics | Maintains: Overweight | $4 → $7 | $2.72 | +157.35% | 2 | Mar 24, 2026 | |
| IMTX Immatics | Assumes: Buy | $18 | $10.35 | +73.91% | 2 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $7 → $8 | $2.48 | +222.58% | 4 | Mar 13, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $125 → $140 | $85.40 | +63.93% | 1 | Feb 26, 2026 | |
| OKYO OKYO Pharma | Initiates: Overweight | $7 | $1.68 | +316.67% | 1 | Feb 20, 2026 | |
| CATX Perspective Therapeutics | Initiates: Overweight | $16 | $4.41 | +262.81% | 1 | Feb 19, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $7 | $4.55 | +53.85% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $27.32 | +75.70% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $23.23 | -31.12% | 12 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $98 | $73.15 | +33.97% | 4 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $67 | $9.67 | +592.86% | 2 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $31 | $8.49 | +265.14% | 2 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $95 | $55.13 | +72.32% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $6 | $4.20 | +42.86% | 1 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $17 | $7.49 | +126.97% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $39.69 | -4.26% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.45 | +120.18% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $34.80 | +104.02% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.17 | +244.15% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $21.84 | -3.85% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $114.77 | +0.20% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $40.41 | -20.81% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.34 | -10.18% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $2.63 | +2,561.60% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.13 | +39,010.43% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.66 | +1,345.78% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.37 | +678.03% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.17 | +293,672.03% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.56 | +119.30% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $57.68 | +75.10% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $131.60 | -47.57% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $438.71 | -64.67% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $5.28 | +2,475.76% | 4 | Mar 6, 2017 |
Regeneron Pharmaceuticals
Mar 31, 2026
Assumes: Overweight
Price Target: $875
Current: $761.85
Upside: +14.85%
Context Therapeutics
Mar 24, 2026
Maintains: Overweight
Price Target: $4 → $7
Current: $2.72
Upside: +157.35%
Immatics
Mar 16, 2026
Assumes: Buy
Price Target: $18
Current: $10.35
Upside: +73.91%
Allogene Therapeutics
Mar 13, 2026
Maintains: Overweight
Price Target: $7 → $8
Current: $2.48
Upside: +222.58%
Kymera Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $125 → $140
Current: $85.40
Upside: +63.93%
OKYO Pharma
Feb 20, 2026
Initiates: Overweight
Price Target: $7
Current: $1.68
Upside: +316.67%
Perspective Therapeutics
Feb 19, 2026
Initiates: Overweight
Price Target: $16
Current: $4.41
Upside: +262.81%
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $4.55
Upside: +53.85%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $27.32
Upside: +75.70%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $23.23
Upside: -31.12%
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $73.15
Upside: +33.97%
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $9.67
Upside: +592.86%
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $8.49
Upside: +265.14%
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $55.13
Upside: +72.32%
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $4.20
Upside: +42.86%
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $7.49
Upside: +126.97%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $39.69
Upside: -4.26%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.45
Upside: +120.18%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $34.80
Upside: +104.02%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $10.17
Upside: +244.15%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $21.84
Upside: -3.85%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $114.77
Upside: +0.20%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $40.41
Upside: -20.81%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.34
Upside: -10.18%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $2.63
Upside: +2,561.60%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.13
Upside: +39,010.43%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $1.66
Upside: +1,345.78%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $4.37
Upside: +678.03%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.17
Upside: +293,672.03%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.56
Upside: +119.30%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $57.68
Upside: +75.10%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $131.60
Upside: -47.57%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $438.71
Upside: -64.67%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $5.28
Upside: +2,475.76%